When should Baxfendy (baxdrostat) be prescribed for hypertension in adult patients whose blood pressure remains above target despite a stable regimen of at least two antihypertensive agents (including a diuretic) and who have no contraindications?

When to Prescribe Baxfendy for Hypertension

Prescribe Baxfendy (baxdrostat) when an adult patient has uncontrolled hypertension (BP ≥140/90 mmHg) despite stable treatment with at least 2 antihypertensive medications including a diuretic, provided their eGFR is ≥45 mL/min/1.73 m² and serum potassium is <5.0 mEq/L. 1

Clinical Scenario for Baxfendy Use

Baxfendy is FDA-approved specifically for combination therapy in adults whose blood pressure remains inadequately controlled on other agents 1. The clinical trial evidence demonstrates efficacy in patients meeting these criteria:

Patient Selection Criteria

• Blood pressure threshold: Seated systolic BP ≥140 mmHg (and <170 mmHg in trials) despite treatment 1
• Background therapy requirement: At least 2 antihypertensive medications, with one being a diuretic 1
• Renal function: eGFR ≥45 mL/min/1.73 m² 1
• Potassium level: Baseline serum potassium ≥3.5 and <5.0 mEq/L 1

Positioning in Treatment Algorithm

The 2025 AHA/ACC guidelines establish the framework for resistant hypertension management 2. While these guidelines recommend mineralocorticoid receptor antagonists (MRAs) as the preferred fourth agent for resistant hypertension with eGFR ≥45 mL/min/1.73 m², Baxfendy represents an alternative aldosterone-targeting strategy when MRAs cannot be used 2, 1.

Specifically consider Baxfendy when:

1. Patient is on optimal triple therapy (ACE inhibitor or ARB + calcium channel blocker + thiazide-like diuretic) but BP remains ≥140/90 mmHg 2
2. MRA is contraindicated or not tolerated (the guidelines list alternative agents for this scenario, and Baxfendy fits this niche as an aldosterone synthase inhibitor) 2
3. Patient cannot use both an ARB and ACE inhibitor simultaneously, or is not on an MRA or potassium-sparing diuretic (trial exclusion criteria that define appropriate use) 1

Expected Blood Pressure Reduction

The BaxHTN trial demonstrated robust efficacy 3:

• Baxdrostat 2 mg: -9.8 mmHg placebo-corrected reduction in seated systolic BP at 12 weeks
• Baxdrostat 1 mg: -8.7 mmHg placebo-corrected reduction
• Both doses showed significant diastolic BP reductions as well

The Bax24 trial confirmed these findings with ambulatory BP monitoring, showing a -14.0 mmHg placebo-corrected reduction in 24-hour ambulatory systolic BP 4. This magnitude of BP reduction is clinically meaningful for cardiovascular risk reduction.

Critical Safety Monitoring

Hyperkalemia Risk

The primary safety concern is hyperkalemia, which occurred more frequently than with placebo 3, 4:

• Potassium >6.0 mmol/L occurred in 2.3-3.0% of patients on baxdrostat vs 0.4% on placebo 3
• Most cases were manageable and did not require permanent discontinuation 3

Monitoring protocol:

• Check serum potassium before initiation (must be <5.0 mEq/L) 1
• Monitor potassium regularly during treatment, especially in the first 12 weeks
• Potassium supplements and binders are permitted but require careful oversight 1

Renal Function Considerations

• Do not use if eGFR <45 mL/min/1.73 m² 1
• Meta-analysis shows modest eGFR reduction of approximately 5.5 mL/min/1.73 m² 5
• Monitor renal function periodically during treatment

Drug Interactions

Baxfendy has minimal clinically significant drug interactions 1:

• No dose adjustment needed with CYP3A inhibitors (tested with itraconazole)
• Does not affect metformin or oral contraceptives
• Cannot be used simultaneously with both an ARB and ACE inhibitor 1
• Cannot be combined with MRAs or other potassium-sparing diuretics 1

Dosing Strategy

Start with 1 mg once daily, which can be increased to 2 mg once daily based on BP response and tolerability 1. The 2 mg dose showed slightly greater efficacy in trials 3. Timing of administration should be at the patient's most convenient time to establish consistent adherence 6.

Common Pitfalls to Avoid

1. Do not prescribe if patient is already on an MRA - this creates redundant aldosterone blockade and excessive hyperkalemia risk 1
2. Do not use in patients with eGFR <45 mL/min/1.73 m² - safety and efficacy not established 1
3. Do not initiate if baseline potassium ≥5.0 mEq/L - unacceptable hyperkalemia risk 1
4. Do not assume this replaces comprehensive resistant hypertension workup - the 2025 AHA/ACC guidelines emphasize evaluating for secondary causes and medication interference before adding agents 2

Comparison to Guideline-Recommended Approach

The 2025 AHA/ACC guidelines recommend MRAs as the preferred add-on for resistant hypertension 2. The 2024 ESC guidelines similarly prioritize traditional agents 6. Baxfendy offers a mechanistically distinct approach to aldosterone reduction - it inhibits aldosterone synthesis rather than blocking its receptor 7. This selectivity (100:1 for aldosterone synthase vs. cortisol synthesis) avoids adrenocortical insufficiency 8.

Given that aldosterone dysregulation is a key driver of resistant hypertension 3, 4, Baxfendy targets the underlying pathophysiology. The drug demonstrated efficacy in a population where 90% were on ACE inhibitors or ARBs, 70% on calcium channel blockers, and 41% on 3 background medications 1.

Patient Population from Trials

The evidence base includes patients with 1, 3:

• Mean age 61 years
• 37% with type 2 diabetes
• 6% with heart failure
• Mean BMI 31 kg/m²
• Mean baseline BP 149/87 mmHg
• Mean eGFR 85 mL/min/1.73 m²

This represents real-world resistant hypertension patients with multiple comorbidities, supporting broad applicability in clinical practice.